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N-acetyltransferase 2 polymorphisms 
are of high relevance in clinical toxicology 
(Lück et al., 2009; Bing et al., 2011; Costa 
et al., 2012). The slow acetylator genotype 
of NAT2 has been demonstrated to be asso-
ciated with an increased risk of anti-
tuberculosis drug-induced liver damage 
(Cai et al., 2012; Lv et al., 2012; An et al., 
2012; Ben Mahmoud et al., 2012; Bose et 
al., 2011). Moreover, many urinary bladder 
carcinogens are substrates of NAT2 (Golka 
et al., 1996; 2002; Vineis et al., 2001; Hung 
et al., 2004; Moore et al., 2011). Large me-
ta-analyses have clearly shown an associa-
tion between slow acetylation genotypes 
and increased risk of bladder cancer (Gar-
cia-Closas et al., 2005; 2011; Sanderson et 
al., 2007; Agúndez et al., 2008; Hein, 2002, 
2006, 2009; Hein and Doll, 2012a, b). 
However, at the level of individual studies 
the results remain controversial. Of 46 stud-
ies included into one of the recent meta-
analysis 35 did not reach statistical signifi-
cance (Moore et al., 2011). 
To clarify the situation a recent study 
has been performed to identify the role of 
‘extreme’ genotypes (Selinski et al., 2013). 
This study is based on a population of 344 
individuals that have been phenotyped by 
the caffeine test (Blaszkewicz, 2004; 
Hakooz, 2009; Jetter et al., 2009). This test 
quantitatively determines the activity of 
NAT2 in vivo. A subgroup with an `ultra-
slow´ in vivo metabolism of caffeine was 
identified. 
Interestingly, these individuals with the 
ultra-slow NAT2 phenotype carried several 
slow acetylator alleles and could be identi-
fied as *6A/*6A, *6A/*7B and *7B/*7B 
genotypes. This combination of slow al-
leles, the ‘ultra-slow genotype’ was further 
tested in 1,712 bladder cancer cases and 
2,020 controls. Remarkably, individuals 
with the ‘ultra-slow’ genotype showed an 
increased odds ratio for bladder cancer risk 
(OR=1.31, P=0.012) whereas the slow 
acetylators in general were not significantly 
associated with cancer risk. 
Currently, a huge number of studies is 
performed to understand the association 
between genetic variations and phenotype 
(Daly, 2013; Stewart and Marchan, 2012; 
Partosch et al., 2013; Sobin et al., 2011; 
Tumer et al., 2012; Zeller et al., 2012; Es-
cobar-García et al., 2012). A special focus 
are drug metabolizing enzymes and their 
role in carcinogenesis (Chen et al., 2012; 
Hanioka et al., 2011; Santovito et al., 2011; 
Fujihara et al., 2011; Lankisch et al., 2008; 
Ulusoy et al., 2007). Genome-wide associa-
tion studies have identified to which degree 
genetic variants influence bladder cancer 
risk (Golka et al., 2011; Selinski et al., 
2011, 2012a, b; Safarinejad et al., 2011; 
Lehmann et al., 2010). However, most of 
these approaches considered only the geno-
type in relation to disease. The present 
study (Selinski et al., 2013) demonstrates 
the importance of understanding the associ-
ation of haplotypes with enzyme activity 
and the relevance of extreme phenotypes. 
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